Ajanta Pharma Reports 20% Increase in PAT for Q2 FY 2026, Declares Interim Dividend

Ajanta Pharma Ltd. reported its Q2 and H1 results for FY 2026, with a 20% increase in Profit After Tax (PAT) for Q2. The company also declared an interim dividend of Rs. 28 per share. The revenue from operations for Q2 stood at Rs. 1,354 crore, up 14% from Q2 FY 2025. The EBITDA for Q2 was Rs. 328 crore, up 5% from Q2 FY 2025. The company's ROCE stood at a healthy level of 30% and RONW at 25%.